MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-11-2026
Stryker Corporation Operating Income 2011-2026 | SYK
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Stryker Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.89 B | 3.69 B | 3.89 B | 2.84 B | 2.58 B | 2.22 B | 2.71 B | 2.54 B | 2.3 B | 2.18 B | 1.86 B | 1.25 B | 1.26 B | 1.74 B | 1.69 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 4.89 B | 1.25 B | 2.51 B |
Quarterly Operating Income Stryker Corporation
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.14 B | 1.11 B | 837 M | 1.08 B | 1.05 B | 972 M | 931 M | 965 M | 735 M | - | 808 M | 772 M | 447 M | - | 574 M | 732 M | 459 M | - | 859 M | -20 M | 635 M | - | 628 M | 613 M | 528 M | - | 576 M | 672 M | 591 M | - | 525 M | 502 M | 556 M | - | 486 M | 500 M | 519 M | - | 378 M | 429 M | 406 M | - | 450 M | 197 M | 131 M | - | 150 M | 290 M | 386 M | - | 450 M | 445 M | 476 M | - | 444 M | 401 M | 423 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.14 B | -20 M | 583 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alphatec Holdings
ATEC
|
-82.1 M | $ 11.75 | -3.29 % | $ 1.76 B |  USA |
 |
BioSig Technologies
BSGM
|
-12.9 M | - | 37.08 % | $ 85.7 M | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
Delcath Systems
DCTH
|
660 K | $ 8.98 | -1.32 % | $ 322 M | USA |
 |
Aziyo Biologics
AZYO
|
-26.9 M | - | 1.37 % | $ 20.5 M | USA |
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M | USA |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
Second Sight Medical Products
EYES
|
-24.7 M | - | -0.97 % | $ 54.4 M | USA |
 |
FONAR Corporation
FONR
|
5.31 M | $ 18.41 | 0.38 % | $ 121 M | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
Inogen
INGN
|
-30.2 M | $ 6.32 | -2.02 % | $ 168 M | USA |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
IRIDEX Corporation
IRIX
|
-10 M | $ 1.35 | - | $ 21.8 M | USA |
 |
IRadimed Corporation
IRMD
|
26.1 M | $ 100.97 | 1.78 % | $ 1.28 B | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
LivaNova PLC
LIVN
|
199 M | $ 62.4 | -1.33 % | $ 3.4 B |  Britain |
 |
LENSAR
LNSR
|
-10.7 M | $ 5.56 | -8.4 % | $ 64 M | USA |
 |
AxoGen
AXGN
|
-7.85 M | $ 32.61 | 2.71 % | $ 1.5 B | USA |
 |
CONMED Corporation
CNMD
|
103 M | $ 36.56 | -0.19 % | $ 1.13 B | USA |
 |
Medtronic PLC
MDT
|
5.96 B | $ 86.58 | -0.68 % | $ 111 B | USA |
 |
NanoVibronix
NAOV
|
-3.58 M | - | - | $ 1.08 M | USA |
 |
Electromed
ELMD
|
9.66 M | $ 24.7 | 0.86 % | $ 209 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
InspireMD
NSPR
|
-49.6 M | $ 1.79 | 3.47 % | $ 115 M |  Israel |
 |
Orthofix Medical
OFIX
|
-81.4 M | $ 11.72 | -1.26 % | $ 464 M |  Curacao |
 |
Cytosorbents Corporation
CTSO
|
-16.8 M | $ 0.7 | 3.3 % | $ 38.1 M | USA |
 |
Aethlon Medical
AEMD
|
-9.34 M | $ 2.16 | -6.09 % | $ 3.37 M | USA |
 |
Profound Medical Corp.
PROF
|
-30.3 M | $ 5.15 | -4.63 % | $ 180 M | Canada |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
Penumbra
PEN
|
189 M | $ 334.17 | -0.41 % | $ 13 B | USA |
 |
AdaptHealth Corp.
AHCO
|
90.9 M | $ 11.48 | 10.7 % | $ 1.55 B | USA |
 |
Myomo
MYO
|
-14.4 M | $ 0.7 | -1.83 % | $ 29.3 M | USA |
 |
Insulet Corporation
PODD
|
474 M | $ 225.5 | -0.7 % | $ 15.9 B | USA |
 |
Nano-X Imaging Ltd.
NNOX
|
-56.7 M | $ 2.4 | -1.64 % | $ 141 M | Israel |
 |
Invacare Corporation
IVC
|
-80.5 M | - | - | $ 24.7 M | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 3.91 | 4.83 % | $ 146 M |  France |
 |
Quanterix Corporation
QTRX
|
-126 M | $ 3.82 | -3.05 % | $ 163 M | USA |
 |
OrthoPediatrics Corp.
KIDS
|
-39.2 M | $ 15.91 | -3.4 % | $ 373 M | USA |
 |
Outset Medical
OM
|
-66.7 M | $ 3.53 | -2.35 % | $ 53.7 K | USA |